Relationships between EGFR Mutation Status of Lung Cancer and Preoperative Factors - Are they Predictive?

Usuda, Katsuo; Sagawa, Motoyasu; Motono, Nozomu; Ueno, Masakatsu; Tanaka, Makoto; Machida, Yuichiro; Matoba, Munetaka; Taniguchi, Mitsuru; Tonami, Hisao; Ueda, Yoshimichi; Sakuma, Tsutomu

doi:10.7314/apjcp.2014.15.2.657

Cited by 42 publications

(38 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Usuda et al reported that mutant EGFR is significantly associated with smaller tumor diameter in chest CT in addition to gender, pure or mixed GGO, adenocarcinoma, never-smoker (Usuda et al, 2014). Our results also showed that pStage and pT status were related to EGFR mutation in overall patients, but not men.…”

Section: Discussionsupporting

confidence: 73%

Epidermal Growth Factor Receptor Mutations in Japanese Men with Lung Adenocarcinomas

Tomita

Ayabe²,

Chosa³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

related with never-smoker, women, adenocarcinoma and Asians (Kosaka et al., 2004;Shigematsu et al., 2005;Mitsudomi et al., 2006). Therefore it might demonstrate the role of histology, sex, lifestyle and ethnicity as variables associated with EGFR mutation. To our knowledge, however, there is only one study that focused on EGFR mutation in men and smokers (D'Angelo et al., 2011). Of great interest, they concluded that a large number of EGFR mutations are found in adenocarcinoma tumor specimen from men and people who smoked Masaki Tomita*, Takanori Ayabe, Eiichi Chosa, Katsuya Kawagoe, Kunihide Nakamura cigarettes. In the present study, we focused on the men with adenocarcinoma patients, and we examined the relationship between EGFR mutation and clinical characteristics.

show abstract

Section: Discussionsupporting

confidence: 73%

Epidermal Growth Factor Receptor Mutations in Japanese Men with Lung Adenocarcinomas

Tomita

Ayabe²,

Chosa³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…In the study, the frequency of EGFR mutations was not associated with early stage disease (stage I to II) after adjusting for age, tumor differentiation, and histological subtype (OR, 1.46; 95% CI, 0.84–2.54; P = 0.18). Conflicting results were reported by Usuda et al [27] in a cohort of 148 Japanese patients with operable lung cancer. The clinical stage of EGFR mutant tumors was significantly earlier than that of wild-type tumors ( P = 0.016).…”

Section: Discussionmentioning

confidence: 85%

The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas

et al. 2016

View full text Add to dashboard Cite

BackgroundThe prognostic role of epidermal growth factor receptor (EGFR) mutations in patients with lung adenocarcinomas remains controversial and the association between EGFR mutations and stage at the time of the initial diagnosis is debatable. In this study, we evaluated the association of EGFR mutations with stage at diagnosis in lung adenocarcinomas.Materials and MethodsWe retrospectively analyzed 1004 consecutive patients who were diagnosed with lung adenocarcinomas and tested for EGFR mutations between June 2011 and December 2014.ResultsEGFR mutations were detected in 49.2% of 1004 patients with lung adenocarcinomas. In multivariable analysis, EGFR mutations were significantly associated with early stage disease (stage I to II) at diagnosis (odds ratio [OR], 0.65; 95% confidence interval [CI], 0.49–0.87; P = 0.003). When adjusted for age, sex, smoking status, and screening, the adjusted proportion of EGFR mutations significantly decreased according to stage. The adjusted proportions of EGFR mutations were 57.6% (95% CI, 51.7%–63.3%) for stage I, 47.9% (95% CI, 36.9%–59.0%) for stage II, 47.5% (95% CI, 39.6%–55.5%) for stage III, and 43.4% (95% CI, 38.3%–48.6%) for stage IV (P = 0.0082).ConclusionsThe presence of EGFR mutations is significantly associated with early stage disease at initial diagnosis in lung adenocarcinomas after adjusting for age, sex, smoking status, and screening. This finding implies that EGFR mutations may play a role as a positive prognostic marker.

show abstract

“…Most reports focused on the presence of any GGO or GGO proportion and some of the findings are conflicting. The definition of GGO proportion differs among studies and the following parameters have been used to calculate the GGO proportion: consolidation/tumor dimension ratio (33,34), GGO/tumor area ratio (35), area ratio of tumor on mediastinal windows to that on lung windows, GGO/tumor volume ratio (6,36,37), and the product of the dimension ratio of the tumor on mediastinal windows to that on lung windows to calculate the tumor shadow disappearance rate (TDR) (37-39).…”

Section: Molecular Pathology and Ct Featuresmentioning

confidence: 99%

Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology

Gao

Rizzo

et al. 2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Relationships between EGFR Mutation Status of Lung Cancer and Preoperative Factors - Are they Predictive?

Cited by 42 publications

References 22 publications

Epidermal Growth Factor Receptor Mutations in Japanese Men with Lung Adenocarcinomas

Epidermal Growth Factor Receptor Mutations in Japanese Men with Lung Adenocarcinomas

The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas

Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology

Contact Info

Product

Resources

About